JAK/STAT signaling
JAK/STAT signaling inhibitors are compounds that disrupt the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, which is involved in cytokine signaling, cell growth, and immune response. These inhibitors are important tools in studying the regulation of this pathway and its role in various diseases, including cancers, immune disorders, and inflammatory conditions. JAK/STAT inhibitors are also being developed as targeted therapies for these diseases. At CymitQuimica, we provide a wide selection of high-quality JAK/STAT signaling inhibitors to support your research in molecular biology, oncology, and immunology.
Subcategories of "JAK/STAT signaling"
Products of "JAK/STAT signaling"
Sort by
Ifidancitinib
CAS:Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39Pim-1/2 kinase inhibitor 1
CAS:Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.Formula:C11H9NO3SPurity:99.89%Color and Shape:SolidMolecular weight:235.26JAK-IN-10
CAS:JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.Formula:C20H18FN5O3SPurity:98.88%Color and Shape:SolidMolecular weight:427.45Ref: TM-T13571
1mg87.00€5mg177.00€10mg260.00€25mg429.00€50mg605.00€100mg815.00€500mg1,624.00€1mL*10mM (DMSO)188.00€JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Formula:C25H33N5O2Color and Shape:SolidMolecular weight:435.56TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormula:C28H32N4O3SPurity:97.38% - 99.1%Color and Shape:SolidMolecular weight:504.64(2R)-Octyl-α-hydroxyglutarate
CAS:(2R)-Octyl-α-hydroxyglutarate ((2R)-Octyl-2-HG) is a D-isomer 2-Hydroxyglutarate modified form.Formula:C13H24O5Color and Shape:SolidMolecular weight:260.33Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89Ref: TM-T12266L2
1mg77.00€5mg165.00€10mg240.00€25mg408.00€50mg562.00€100mg800.00€200mg1,074.00€1mL*10mM (DMSO)177.00€G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purity:97.30%Color and Shape:SolidMolecular weight:383.39Ref: TM-T8742
1mg50.00€5mg97.00€10mg145.00€25mg259.00€50mg374.00€100mg523.00€200mg710.00€1mL*10mM (DMSO)105.00€2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFormula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24Ref: TM-T22416
1mg64.00€2mg87.00€5mg117.00€10mg183.00€25mg354.00€50mg520.00€100mg702.00€200mg944.00€1mL*10mM (DMSO)140.00€JAK-IN-5 hydrochloride
CAS:JAK-IN-5 hydrochloride is a JAK inhibitor [1].Formula:C27H32ClFN6OColor and Shape:SolidMolecular weight:511.03Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Formula:C19H19F2N7O3Color and Shape:SolidMolecular weight:431.40JAK/HDAC-IN-2
JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.Formula:C28H38N6O5SPurity:98%Color and Shape:SolidMolecular weight:570.7SGI-1776
CAS:SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.Formula:C20H22F3N5OPurity:100% - 99.84%Color and Shape:SolidMolecular weight:405.42Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51Ref: TM-T67907
1mg96.00€2mg139.00€5mg227.00€10mg354.00€25mg653.00€50mg938.00€100mg1,454.00€500mg2,822.00€JAK2-IN-6
CAS:JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.Formula:C14H10ClN3OS2Purity:99.38%Color and Shape:SolidMolecular weight:335.83JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Formula:C25H32N8O2Purity:99.64%Color and Shape:SolidMolecular weight:476.57WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formula:C19H18ClN5Color and Shape:SolidMolecular weight:351.833GDC-0339
CAS:GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formula:C20H22F3N7OSColor and Shape:SolidMolecular weight:465.5Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formula:C18H19F3N6OPurity:100% - 99.45%Color and Shape:SolidMolecular weight:392.38Ref: TM-T2636
1mg38.00€2mg52.00€5mg79.00€10mg110.00€25mg217.00€50mg329.00€100mg494.00€200mg705.00€1mL*10mM (DMSO)88.00€Pim1/AKK1-IN-1
CAS:Pim1/AKK1-IN-1: LKB1/AAK1 inhibitor with Kd 35/53/75/380 nM for Pim1/AKK1/MST2/LKB1, also targets MPSK1, TNIK.Formula:C20H13N5OPurity:97.84% - 98.69%Color and Shape:SolidMolecular weight:339.35Ref: TM-T5093
1mg89.00€2mg131.00€5mg183.00€10mg278.00€25mg490.00€50mg710.00€100mg998.00€1mL*10mM (DMSO)202.00€Pacritinib
CAS:Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).Formula:C28H32N4O3Purity:99.25% - 99.49%Color and Shape:SolidMolecular weight:472.58CX-6258
CAS:CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.Formula:C26H24ClN3O3Purity:95.88%Color and Shape:SolidMolecular weight:461.94Ref: TM-T1834
1mg37.00€5mg80.00€10mg106.00€25mg208.00€50mg311.00€100mg472.00€200mg658.00€1mL*10mM (DMSO)81.00€Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94Ref: TM-T2638
5mg51.00€10mg88.00€25mg160.00€50mg296.00€100mg469.00€500mg1,035.00€1mL*10mM (DMSO)57.00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formula:C26H33N7OPurity:98.71%Color and Shape:SolidMolecular weight:459.59Ref: TM-T35900
1mg145.00€5mg354.00€10mg630.00€25mg1,301.00€50mg1,738.00€100mg2,357.00€1mL*10mM (DMSO)358.00€AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Formula:C20H28FN7Purity:98%Color and Shape:SolidMolecular weight:385.48JBJ-04-125-02
CAS:JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.Formula:C29H26FN5O3SPurity:98%Color and Shape:SolidMolecular weight:543.61JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFormula:C17H20N6OPurity:98.81%Color and Shape:SolidMolecular weight:324.38Quercetagetin
CAS:Quercetagetin, a flavonoid from Citrus unshiu, inhibits pim-1 kinase (IC50: 0.34 μM), cell-permeable.Formula:C15H10O8Purity:99.65% - 99.76%Color and Shape:SolidMolecular weight:318.24Ref: TM-T8114
1mg88.00€5mg202.00€10mg303.00€25mg510.00€50mg733.00€100mg998.00€500mg1,985.00€1mL*10mM (DMSO)213.00€DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Formula:C17H20N8O2SPurity:99.89%Color and Shape:SoildMolecular weight:400.46RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formula:C29H35N7O4Purity:97.29% - 99.91%Color and Shape:SolidMolecular weight:545.63STAT3-IN-18
CAS:STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells andFormula:C18H24Cl2N2O6PtPurity:98%Color and Shape:SolidMolecular weight:630.38Cerdulatinib
CAS:Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.Formula:C20H27N7O3SPurity:98.74% - 99.49%Color and Shape:SolidMolecular weight:445.54Ref: TM-T2487
1mg44.00€2mg55.00€5mg79.00€10mg106.00€25mg185.00€50mg283.00€100mg432.00€200mg605.00€500mg938.00€1mL*10mM (DMSO)86.00€Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Formula:C20H26O5Purity:100% - 99.74%Color and Shape:SolidMolecular weight:346.42Ref: TM-T4672
1mg96.00€5mg215.00€10mg369.00€25mg610.00€50mg840.00€100mg1,130.00€500mg2,308.00€1mL*10mM (DMSO)235.00€(Z)-SMI-4a
CAS:(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.Formula:C11H6F3NO2SPurity:97.66% - 99.44%Color and Shape:SolidMolecular weight:273.23K00135
CAS:K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.Formula:C18H18N4OPurity:97.88%Color and Shape:SolidMolecular weight:306.36Ref: TM-T27704
1mg185.00€2mg279.00€5mg426.00€10mg627.00€25mg938.00€50mg1,320.00€100mg1,786.00€500mg3,591.00€1mL*10mM (DMSO)415.00€JAK-IN-14
CAS:JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.Formula:C19H15FN4OPurity:98.27%Color and Shape:SolidMolecular weight:334.35Ref: TM-T9764
1mg139.00€5mg330.00€10mg492.00€25mg797.00€50mg1,103.00€100mg1,491.00€200mg1,985.00€1mL*10mM (DMSO)340.00€STAT5-IN-3
STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.Formula:C25H27N5OColor and Shape:SolidMolecular weight:413.51JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormula:C19H18N4O3Purity:97.46% - 99.94%Color and Shape:SolidMolecular weight:350.37CEP-33779
CAS:CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.Formula:C24H26N6O2SPurity:98.81% - ≥95%Color and Shape:SolidMolecular weight:462.57Ref: TM-T6122
1mg46.00€2mg59.00€5mg87.00€10mg144.00€25mg245.00€50mg376.00€100mg560.00€500mg1,216.00€1mL*10mM (DMSO)97.00€JAK1-IN-11
CAS:JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.Formula:C26H36N6O4SPurity:98%Color and Shape:SolidMolecular weight:528.67Lorpucitinib
CAS:Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5Izencitinib
CAS:Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.Formula:C22H26N8Purity:99.82%Color and Shape:SolidMolecular weight:402.50Ref: TM-T35898
1mg88.00€5mg187.00€10mg298.00€25mg597.00€50mg938.00€100mg1,510.00€200mg2,072.00€1mL*10mM (DMSO)207.00€VB1080
VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5 µM for PIM1, 4996 µM for PIM2, and 9.88 µM for PIM3. Additionally, VB1080 exhibits cytotoxic properties and possesses anthelmintic activity.Formula:C27H27N3O3Molecular weight:441.522Pim-1 kinase inhibitor 5
CAS:Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-Formula:C22H13Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:406.26
